KKR's $5.7B Bet on MedTech: Inside the Integer Acquisition

PLANO, Texas and NEW YORK – August 03, 2026 – In a move that underscores the immense value of the behind-the-scenes players in medical technology, global investment firm KKR has announced a definitive agreement to acquire Integer Holdings Corporation (NYSE: ITGR) in an all-cash transaction valued at approximately $5.7 billion. The deal will see Integer, one of the world's largest medical device contract development and manufacturing organizations (CDMOs), transition from a publicly traded entity to a privately held company.

Under the terms of the agreement, KKR will pay $127 per share for all outstanding shares of Integer. This price represents a substantial 51.8% premium over the company's closing stock price on April 29, 2026, the day before Integer announced it was launching a comprehensive strategic review. The acquisition, which is expected to close by the end of the year pending stockholder and regulatory approvals, marks one of the most significant private equity buyouts in the medical device sector in recent memory.

A Strategic Bet on Medical Device Manufacturing

KKR's acquisition is a calculated bet on the growing importance of specialized manufacturing within the healthcare ecosystem. Integer is a critical partner for many of the world's leading medical device companies, providing essential engineering and manufacturing for complex devices in the cardio and vascular, neuromodulation, and cardiac rhythm management markets. This specialization in high-growth, durable end-markets makes it a highly attractive asset.

"Integer is an exceptional platform with highly differentiated capabilities across a global manufacturing footprint, a track record for quality and reliability, and a talented team," said Max Lin, Partner at KKR. "We are excited by the opportunity to deploy capital and resources to further advance Integer’s next chapter of growth and innovation."

This investment aligns perfectly with KKR's established strategy of acquiring market leaders in resilient industries. The firm has a long history of major healthcare investments, including the $9.9 billion take-private deal for Envision Healthcare in 2018. By adding Integer to its portfolio, KKR deepens its exposure to the medical technology supply chain, capitalizing on the accelerating trend of device companies outsourcing development and manufacturing to focus on their core competencies of research and marketing.

Integer’s Next Chapter Under Private Ownership

For Integer, the move to private ownership under KKR's stewardship promises a new era of strategic flexibility and long-term investment. Freed from the quarterly pressures of public market reporting, the company will have greater latitude to pour capital into innovation, technology upgrades, and capacity expansion—initiatives that are crucial for staying ahead in the fast-paced MedTech landscape.

"We believe this transaction recognizes the strength of Integer’s business... while providing stockholders with immediate and certain value," said Payman Khales, Integer’s President and CEO. "KKR’s deep healthcare expertise, long-term vision, and strategic growth orientation make them the right strategic partner to bring our business into its next chapter."

A cornerstone of KKR's value-creation strategy is its commitment to broad-based employee ownership. The firm intends to establish an employee ownership and engagement program for Integer's 11,000 associates following the transaction's close. This approach, which KKR has implemented across more than 90 portfolio companies, aims to align the interests of employees with the long-term success of the business, fostering a culture of shared ownership and potentially boosting productivity and retention.

The Path to the Deal: Activism, Rumors, and a Hefty Premium

The acquisition follows a period of significant activity for Integer. The company's board initiated its strategic review after facing pressure from activist investor Irenic Capital Management, which had become one of its largest shareholders. The pressure culminated in the appointment of two new directors to Integer’s board in March 2026, setting the stage for a re-evaluation of the company's path forward.

Market anticipation for a deal reached a fever pitch on July 31, when reports first surfaced that KKR was nearing an agreement. The news caused Integer's stock to surge by nearly 20% in a single day, with trading briefly halted due to volatility. The final offer price of $127 per share validates that market enthusiasm, representing a valuation that analysts had been anticipating as the company's performance metrics showed underlying strength despite a temporary dip in earnings expected for 2026. The significant premium underscores KKR's conviction in Integer’s intrinsic value and its future growth prospects.

A Bellwether for MedTech Consolidation

This blockbuster deal is more than just a transaction between two companies; it is a powerful indicator of broader trends reshaping the global medical technology industry. The CDMO sector is undergoing a period of intense consolidation as private equity firms, armed with vast amounts of capital, seek to invest in recession-resistant sectors with strong growth fundamentals.

The Integer-KKR deal mirrors other recent private equity buyouts in healthcare, highlighting a clear appetite for companies that form the critical backbone of the medical supply chain. As medical devices become more complex and regulatory hurdles increase, the specialized expertise offered by CDMOs like Integer becomes indispensable. By taking Integer private, KKR is positioning itself to capitalize on this long-term, non-discretionary demand. Upon completion of the transaction, Integer's stock will be delisted from the New York Stock Exchange, marking a new, private chapter for the MedTech manufacturing powerhouse.